[HTML] springer.comFull View

[HTML][HTML] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran, ID Davis… - BMC medicine, 2022 - Springer
Background Both changes in circulating lipids represented by a validated poor prognostic 3-
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …
被引用次数：19 相关文章
[PDF] unimelb.edu.au

[PDF][PDF] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - 2022 - minerva-access.unimelb.edu.au
Background: Both changes in circulating lipids represented by a validated poor prognostic 3‑
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - BMC …, 2022 - research.monash.edu
Background: Both changes in circulating lipids represented by a validated poor prognostic 3-
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - BMC Medicine, 2022 - europepmc.org
Background Both changes in circulating lipids represented by a validated poor prognostic 3-
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - BMC …, 2022 - research.sahmri.org.au
Background: Both changes in circulating lipids represented by a validated poor prognostic 3-
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …
[HTML] nih.gov

[HTML][HTML] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - BMC …, 2022 - ncbi.nlm.nih.gov
Background Both changes in circulating lipids represented by a validated poor prognostic 3-
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …
[PDF] core.ac.uk

[PDF][PDF] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran, ID Davis… - 2022 - core.ac.uk
Background: Both changes in circulating lipids represented by a validated poor prognostic 3‑
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …
[HTML] biomedcentral.com

[HTML][HTML] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke… - BMC …, 2022 - bmcmedicine.biomedcentral.com
Both changes in circulating lipids represented by a validated poor prognostic 3-lipid
signature (3LS) and somatic tumour genetic aberrations are individually associated with …

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - BMC …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Both changes in circulating lipids represented by a validated poor prognostic 3-
lipid signature (3LS) and somatic tumour genetic aberrations are individually associated …

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.

B Mak, HM Lin, EM Kwan, H Fettke, B Tran… - BMC …, 2022 - search.ebscohost.com
Abstract < bold> Background: </bold> Both changes in circulating lipids
represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour …